Cullinan Oncology, Inc. (CGEM) Key Metrics
CGEM valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $794.7M
- Enterprise value
- $752.6M
- P/E (TTM)
- —
- Forward P/E
- 6.7
- PEG ratio
- —
- Price / sales
- 25.9
- Price / book
- 3.4 10-yr median 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.04
CGEM key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCGEM valuation Price multiples at each fiscal year-end price.
CGEM returns How much profit the business earns on the capital it uses.
CGEM per-share figures Results divided by the shares outstanding at year-end.
CGEM financial health Debt, liquidity and how easily interest is covered.
CGEM efficiency & capital use Working capital cycle and where the cash goes.
CGEM valuation history
CGEM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CGEM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CGEM cash returned to shareholders
CGEM price vs earnings per share
CGEM key metrics
2015–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $611.2M | $654.9M | $423.4M | $492.1M | $683.4M | — | — | — | — | — |
| Enterprise value | $236.0M | $258.1M | −$40.1M | $29.9M | $393.0M | — | — | — | — | — |
| P/E ratio | — | — | — | 4.4 | — | — | — | — | — | — |
| Price / sales | — | — | — | — | 36.1 | — | — | — | — | — |
| Price / book | 1.5 | 1.1 | 0.9 | 0.9 | 1.6 | — | — | — | — | — |
| EV / sales | — | — | — | — | 20.7 | — | — | — | — | — |
| Earnings yield | −36.0% | −25.6% | −36.2% | 22.6% | −9.5% | — | — | — | — | — |
| Free cash flow yield | −28.8% | −22.2% | −31.8% | −26.0% | −6.4% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 4.8% | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $10.35 | $12.18 | $10.19 | $10.55 | $15.43 | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.43 | $0.44 | — | — | — | — |
| Earnings per share | −$3.72 | −$3.11 | −$3.69 | $2.38 | −$1.47 | −$1.17 | — | — | — | — |
| Operating cash flow per share | −$2.98 | −$2.70 | −$3.23 | −$2.72 | −$0.98 | −$0.68 | — | — | — | — |
| Free cash flow per share | −$2.98 | −$2.70 | −$3.24 | −$2.74 | −$0.99 | −$0.68 | — | — | — | — |
| Cash per share | $6.40 | $7.42 | $11.24 | $10.02 | $6.56 | $4.83 | — | — | — | — |
| Book value per share | $6.92 | $10.98 | $10.92 | $11.47 | $9.59 | $4.57 | — | — | — | — |
| Tangible book value per share | $6.92 | $10.98 | $10.92 | $11.47 | $9.59 | $4.57 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.01 | $0.02 | $0.01 | $0.00 | — | — | — | — |
| Debt per share | $0.05 | $0.04 | $0.09 | $0.11 | — | — | — | — | — | — |
| Shares outstanding | 59.0M | 53.8M | 41.5M | 46.6M | 44.3M | 43.5M | — | — | — | — |
| Change in shares outstanding | +9.8% | +29.4% | −10.9% | +5.3% | +1.8% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −44.0% | −32.1% | −31.0% | 23.2% | −20.8% | −64.3% | — | — | — | — |
| Return on invested capital (ROIC) | −168.2% | −169.3% | — | 100.6% | −87.1% | — | — | — | −30.7% | −7.8% |
| Return on assets (ROA) | −41.1% | −30.3% | −29.3% | 22.3% | −20.0% | −32.3% | −29.7% | −81.9% | — | — |
| Return on tangible assets | −49.0% | −26.9% | −31.6% | 19.8% | −14.9% | −23.7% | −19.9% | −41.0% | — | — |
| Free cash flow margin | — | — | — | — | −232.4% | −157.2% | — | — | — | — |
| Income quality (OCF / net income) | — | — | — | −1.14 | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2.7M | $2.2M | $3.6M | $5.2M | — | — | — | — | $660,816 | $2.2M |
| Cash & short-term investments | $377.9M | $399.0M | $467.1M | $467.3M | $290.5M | $210.2M | $98.6M | $33.8M | $91 | $118 |
| Net debt | −$375.2M | −$396.8M | −$463.5M | −$462.1M | −$290.5M | −$210.2M | −$98.6M | −$33.8M | $660,725 | $2.2M |
| Debt / equity | 0.01 | 0.00 | 0.01 | 0.01 | — | — | — | — | — | — |
| Debt / assets | 0.01 | 0.00 | 0.01 | 0.01 | — | — | — | — | 192.38 | 18,443.64 |
| Current ratio | 10.25 | 13.53 | 17.07 | 21.09 | 25.25 | 14.82 | 39.67 | 25.85 | 0.01 | 0.00 |
| Quick ratio | 10.25 | 13.53 | 17.26 | 21.09 | 25.25 | 14.82 | 39.67 | 25.85 | 0.01 | 0.00 |
| Interest coverage | — | — | — | 0.3 | -1.0 | -67.9 | — | — | — | — |
| Working capital | $349.0M | $384.0M | $452.1M | $452.0M | $284.8M | $198.0M | $97.6M | $32.9M | −$244,442 | −$156,624 |
| Invested capital | $33.5M | $193.5M | −$9.8M | $72.9M | $134.5M | −$11.2M | −$139.4M | −$54.5M | $85,875 | $931,433 |
| Tangible asset value | $408.7M | $590.3M | $453.9M | $535.0M | $425.4M | $200.3M | −$39.9M | −$20.6M | −$574,850 | −$1.2M |
| Net current asset value | $347.1M | $383.2M | $449.9M | $448.4M | $284.8M | $197.9M | −$40.3M | −$21.1M | −$574,850 | −$1.2M |
| Graham number | — | — | — | $24.81 | — | — | — | — | — | — |
| Graham net-net per share | $5.73 | $6.88 | $10.54 | $9.46 | $6.29 | $4.50 | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $23.7M | $0 | $213,000 | $378,000 | $21,000 | $0 | $0 |
| Capex / revenue | — | — | — | — | 3.1% | 0.1% | — | — | — | — |
| Capex / depreciation | 0.16 | 0.00 | 0.67 | 12.18 | 11.12 | 0.16 | 0.29 | 6.07 | — | — |
| Stock-based compensation / revenue | — | — | — | — | 128.7% | 78.7% | — | — | — | — |
| R&D / revenue | — | — | — | — | 304.9% | 228.1% | — | — | — | — |
| SG&A / revenue | — | — | — | — | 153.9% | 90.4% | — | — | — | — |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | -6,358.1 | — | — | — | — | — | — | — |
| Days payables outstanding | 1,480.5 | 2,490.0 | 3,033.6 | 11,438.6 | 44,240.8 | 31,239.9 | 3,206.8 | 2,308.3 | — | — |
| Receivables turnover | — | 0.00 | 0.00 | — | — | — | — | — | 0.00 | — |
| Payables turnover | 0.25 | 0.15 | 0.12 | 0.03 | 0.01 | 0.01 | 0.11 | 0.16 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $4.2M | $5.4M | — | — | — | — | — | $3,344 | — |
| Average payables | $1.3M | $2.1M | $2.6M | $2.9M | $6.4M | $5.3M | $615,000 | $271,938 | $202,310 | $121,087 |
| Average inventory | — | — | −$5.4M | — | — | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CGEM's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CGEM valuation and financial ratios
Cullinan Oncology earned a return on equity of −44.0% and a return on invested capital of −168.2% in fiscal 2025. It ended the year with $2.7 million of debt and $377.9 million in cash and short-term investments, a net cash position of $375.2 million.
See the CGEM income statement, the CGEM chart for price history, or the CGEM stock overview for the latest quote and news.
CGEM key metrics FAQ
What is Cullinan Oncology's return on equity?
Cullinan Oncology's return on equity (ROE) was −44.0% in fiscal 2025: net income of -$219.9 million on average shareholders' equity of $499.5 million.
What is Cullinan Oncology's ROIC?
Cullinan Oncology's return on invested capital was −168.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Cullinan Oncology have?
Cullinan Oncology had total debt of $2.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Cullinan Oncology's free cash flow yield?
Cullinan Oncology generated -$175.8 million of free cash flow in fiscal 2025, a free cash flow yield of −28.8% on its market value at year-end ($611.2 million).
What is Cullinan Oncology's current ratio?
Cullinan Oncology's current ratio was 10.25 at the end of fiscal 2025: current assets were 10.25 times current liabilities.